Halberd Corporation Discusses Qualitative & Quantitative Diagnostic Methodology for Detecting COVID-19 Antibodies and Antigens with The Stock Day Podcast
Phoenix, AZ January 28th, 2021 (Newsfile Corp.) — The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including COVID-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly.
“The first part I would like to talk about is the fluorescent and non-fluorescent monoclonal antibodies. What are those exactly?” asked Jolly to begin the interview. “Antibodies work against disease antigens, and antibodies and antigens attract each other like ionic attraction. If you have antibodies present, what they do fundamentally is conjoin with disease antigens, the bad stuff, and in effect they can then be eliminated,” explained Hartman. “We have fluorescent and non-fluorescent antibodies,” he continued. “Non-fluorescent are your standard antibodies. We have multiple non-fluorescent antibodies, and we also have multiple fluorescent antibodies. Fluorescent antibodies can be used very effectively in detection systems and improve the efficacy or efficiency of detection systems,” said Hartman. “For example, fluorescent antibodies can be used against COVID-19.”
“I understand Halberd Corporation is or has been working on an antibody cocktail, if you will. What exactly is that?” asked Jolly. “A monoclonal antibody has a degree of effectiveness in terms of the strength of it, as well as the attractiveness to the disease antigens,” explained Hartman, noting that the efficiency of antibodies can be improved when combined. “So, we have developed an antibody cocktail simply because it’s so much more efficient than antibodies alone.”
“How is your radio frequency project coming along?” asked Jolly. “Radio frequency is an entirely new approach. What we do is we conjoin a metallic moiety, which is literally another item conjoined to an antibody, and of course then that attracts the antigen,” said Hartman. “By coming up with the exact radio frequency, you can destroy the conjoined metallic moiety-antibody-antigen complex and eliminate the disease antigen from the blood or whatever you happen to be using as a medium,” said Hartman. “This radio frequency is a patent-pending mechanism by Halberd, and we’re working on this with several universities.”
Jolly then asked about the Company’s immunity booster strategy. “We’ve come up with our own immunity booster strategy in terms of developing vitamin complexes that in fact produce an immunity against COVID-19,” he shared. “This could be used by not only those that get the vaccine, but also those who have not yet had the vaccine,” said Hartman. “We’re very pleased with that and we will be bringing this product out shortly. We’re talking to manufacturers to build under a non-disclosure agreement so that they can build our exact formulation.”
The conversation then turned to the qualitative and quantitative measurement of COVID-19 antibodies and antigens. “During the development of our fluorescent antibody, in determining what we could and could not do with it and how it could make a more effective measurement of disease infestation, degree and/or freedom from disease, in terms of the antibody that is present in the blood, we’ve developed a methodology whereas we can use our fluorescent antibody as a tool to measure the precise degree of antibody and/or antigen present in the blood,” said Hartman. “Today’s testing mechanism that you find commercially available tests ‘yes’ or ‘no’ for antibodies; we measure the precise amount of antibodies and/or antigens present,” he continued, adding that the mechanism can also measure the effectiveness of a patient’s COVID-19 treatment.
“This could be a tremendous boom to the industry worldwide. This could test whether or not people need the vaccine, whether or not the vaccine was effective, whether or not the treatment was effective. This could be a real blockbuster,” said Hartman.
“The more technology we have, the more attractive we become to Big Pharma. The simple truth is that Halberd Corporation has a lot of technology, we put out a lot of press releases, and we’re trying to make ourselves more attractive to where we can license the technology, sell it, and etc.,” shared Hartman. “With all of the technology that we have, we have three issued patents. In the last couple of months, we put out eight provisional patent applications! That is I think among some of the best of the industry. We have a lot of technology and we’re a great investment.”
“What do you think is going to be the catalyst to move your company forward?” asked Jolly. “We’re doing a multifaceted approach. Number one, develop a lot of technology. Number two, we’ve contracted with Arizona State University, and they’re the best in the industry according to the U.S. News and World Report. We’re also working with other universities to supplement them,” said Hartman, adding the Company also has a strong focus on communications and publishing regular press releases to build interest and awareness. “We have great people. In fact, among the best in the industry. Frankly, the end result for us is to develop a lot of technology, patent it, and present ourselves to the industry and to our stockholders. We think that is the key to success.”
To hear Bill Hartman’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7784371-halberd-corporation-discusses-qualitative-quantitative-diagnostic-methodology-for-detecting-cov
Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/
About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;”“Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” and “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;”“Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” and “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media